Effect of ACE inhibitors and β-blockers on homocysteine levels in essential hypertension

Journal of Human Hypertension

Volumn 22, Issue 4, 2008, Pages 289-294

  Poduri, A ^a   Kaur, J ^a   Thakur, J S ^a   Kumari, S ^a   Jain, S ^a   Khullar, M ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; RAMIPRIL; THYMINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DNA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 41049112929     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002325     Document Type: Article

References (54)

1. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18: 73-78.
2. Chaturvedi S, Pant M, Neelam, Yadav G. Hypertension in Delhi: prevalence, awareness, treatment and control. Trop Doct 2007; 37: 142-145.
3. Singh RB, Beegom R, Mehta AS, Niaz MA, De AK, Haque M et al. Prevalence and risk factors of hypertension and age specific blood pressures in five cities; a study in Indian women. NKP Salve Institute of Medical Sciences, Nagpur, India Five City Study Group. Int J Cardiol 1998; 63: 165-173.
4. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C et al Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216.
5. Lim U, Cassano PA. Homocysteine and blood pressure in the third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156: 1105-1113.
6. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE et al. Total plasma homocysteine and cardiovascular risk profile, The Hordaland Homocysteine study. JAMA 1995; 274: 1526-1533.
7. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr 2001; 73: 613-621.
8. Kahleova R, Palyzova D, Zvara K, Zvárová J, Hrach K, Nováková I et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857-864.
9. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels as are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-1749.
10. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocyst(e)ine levels in essential hypertension: Relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14: 627-631.
11. Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000; 13 14-20.
12. Neugebauer S, Tarnow L, Stehouwer C, Teerlink T, Baba T, Watanabe T et al. Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia 2002; 45: 1315-1324.
13. van Guldener C, Nanayakkara. PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep 2003; 5: 26-31.
14. Sundstrom J, Sullivan L, D'Agostino RB, Jacques PF, Selhub J, Rosenberg IH et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: The Framingham Heart study. Hypertension 2003; 42: 1100-1105.
15. Pierdomenico SD, Bucci A, Lapenna D, Lattanzio FM, Talone L, Cuccurullo F et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-170.
16. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM et al. Hyperhomocysteinemia-induced vascular damage in the mini pig: captopril-hydrochloro-thiazide combination prevents elastic alterations. Circulation, 1995; 91: 1161-1174.
17. Curgunlu A, Karter Y, Uzun H, Aydin S, Erturk N, Vehid S et al. Hyperhomocysteinemia: An additional risk factor in white coat hypertension. Int Heart J 2005; 46: 245-254.
18. Jain S, Ram H, Kumari S, Khullar M. Plasma homocysteine levels in Indian patients with essential hypertension and their siblings. Ben Fail 2003; 25: 195-201.
19. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
20. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homacysteine metabolism: Impact on cardiovascular risk. Drugs 2002; 62: 605-616.
21. Morrow LE, Grimsley EW. Long-term diuretic therapy in hypertensive patients: Effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. South Med J 1999; 92: 866-870.
22. Westphal S, Rading A, Luley C, Dierkes J. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003; 52: 261-263.
23. Chobanian AV, Bakris GL, Black HR, Green LA, Izzo Jr JL, Jones DW et al. Seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
24. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534-2544.
25. Jonkers IJ, de Man FH, Onkenhout W, van der Laarse A, Smelt AH. Implication of fibrate therapy for homocysteine. Lancet 1999; 354: 1208.
26. Atar I, Korkmaz ME, Demircan S, Atar IA, Bozbas H, Aydinalp A et al Beta blocker effects on plasma homocysteinepatients with hypertension. Atherosclerosis 2005; 2: 399-402.
27. Korkmaz ME, Atar I, Tayfun E, Yildirir A, Ulucam. M, Ozin B et al. Effects of a betablocker and spironolactone on plasma homocysteine levels. Int J Cardiol 2003; 88: 119-120.
28. Joint National Committee on Prevention Detection Evaluation, and Treatment of High Blood Preasure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003; 289: 2560-2572.
29. Lahiri DK, Nurnberger Jr JL. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Res 1991; 19: 5444.
30. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al A candidate genetic risk factor for vascular disease: A common mutation in, methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
31. Wong PC, Hart SD, Duncia JV, Timmermans PB. Nonpeptide angiotensin Il receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991; 202: 323-330.
32. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992; 19: 753-757.
33. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells, a novel autocrine function. Cell Regul 1990; 1 649-659.
34. Nagy L, Tarjan J, Samoczi M, Kovacs I, Takacs J. Effect of benazepril on endothelial function in previously untreated hypertensive patients. The Working Group of Cardiology of the Academic Committee of Veszprem, Hungary. Am J Ther 1998; 5: 233-236.
35. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Luscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994; 89: 2212-2218.
36. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95:1119-1121.
37. Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial, endothelial function. Can J Physiol Pharm 1999; 77: 950-957.
38. Bonaventura D, Tirapelli CR, Haddad R, Hoehr NF, Eberlin MN, De Oliveira AM. Chronic methionine load-induced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology 2004; 70: 91-99.
39. Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C et al. A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients - a family-based association study. Clin Exp Hypertens 2005; 6: 509-521.
40. Sharabi Y, Doolman R, Rosenthal T, Grossman E, Rachima-Maoz C, Nussinovitch N et al. Homocysteine. levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens 1999; 12: 766771.
41. Do KQ, Benz B, Sorg O, Pellerin L, Magistretti PJ. Beta-adrenergic stimulation promotes homocysteinic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission. J Neurochem 1997; 68: 2386-2394.
42. Basu TK, Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic efkas. J Nutr 1997; 127 117-121.
43. Selhub J. The many facets of hyperhomocysteinemia: Studies from the Framingham cohorts. J Nutr 2006; 136: 1726S-1730S.
44. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events. Potential mediating mechanisms. Circulation 2007; 16: 2110-2118.
45. Sotgia S, Carru C, Caria MA, Tadolini B, Deiana L, Zinellu A. Acute variations in homocysteine levels are related to creatine changes induced by physical activity. Clin Nutr 2007; 26: 444-449.
46. Kumar J, Das SK, Sharma P, Karthikeyan G, Ramakrishnan L, Sengupta S. Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. J Hum Genet 2005; 50: 655-663.
47. Markan S, Sachdeva M, Sehrawat BS, Kumari S, Jain S, Khullar M. MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians. Mol Cell Biochem 2007; 302: 125-131.
48. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005; 5: 124-139.
49. Schelleman H, Stricker BH, Verschuren WM, de Boer A, Kroon AA, de Leeuw PW et al. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics 2006; 6: 22-26.
50. Westphel S, Rading A, Luley C, Dierkes J. Antihypertensive treatment and homocysteine concentration Metabolism 2003. 52: 261-263.
51. Freis Ed. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995; 122: 223-226.
52. Muda P, Kampus P, Zilmer M, Ristimäe T, Fischer K, Zilmer K et al Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin oncentrations in patients with essential hypertension. J Hypertens 2005; 23: 105-112.
53. Inamoto N, Katsuya T, Kokubo Y, Mannami T, Asai T, Baba S et al. Association of methfylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 2003; 34: 1628-1633.
54. Stephanie H, Fabien M, Rod A, Micky O, Lofti T, Lyn RG. The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 2004; 27: 663-667.